BG109003A - Means for selective suppression of the activity of pathologic autoreactive b-cells - Google Patents

Means for selective suppression of the activity of pathologic autoreactive b-cells

Info

Publication number
BG109003A
BG109003A BG109003A BG10900305A BG109003A BG 109003 A BG109003 A BG 109003A BG 109003 A BG109003 A BG 109003A BG 10900305 A BG10900305 A BG 10900305A BG 109003 A BG109003 A BG 109003A
Authority
BG
Bulgaria
Prior art keywords
cells
autoreactive
pathologic
activity
selective suppression
Prior art date
Application number
BG109003A
Other languages
Bulgarian (bg)
Other versions
BG65954B1 (en
Inventor
Чавдар ВАСИЛЕВ
Андрей ЧОРБАНОВ
Original Assignee
Чавдар ВАСИЛЕВ
Андрей ЧОРБАНОВ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чавдар ВАСИЛЕВ, Андрей ЧОРБАНОВ filed Critical Чавдар ВАСИЛЕВ
Priority to BG109003A priority Critical patent/BG65954B1/en
Priority to PCT/BG2006/000001 priority patent/WO2006072152A2/en
Priority to EP06703172A priority patent/EP1844075A2/en
Publication of BG109003A publication Critical patent/BG109003A/en
Publication of BG65954B1 publication Critical patent/BG65954B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to a means for selective suppression of the activity of pathologic autoreactive B-cells in cases of autoreactive diseases. By their nature it is in the form of a chimerical molecule, comprising immunoglobulin G carrier and two synthetic components, the first one of which is specifically bound to the inhibition surfactant receptor CD22, and the second one --to the immunoglobulin receptors of the B-cells, identifying a selected autoantigene.
BG109003A 2005-01-05 2005-01-05 Means for selective suppression of the activity of pathologic autoreactive b-cells BG65954B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
BG109003A BG65954B1 (en) 2005-01-05 2005-01-05 Means for selective suppression of the activity of pathologic autoreactive b-cells
PCT/BG2006/000001 WO2006072152A2 (en) 2005-01-05 2006-01-04 Suppressor of disease-associated autoreactive b iymphocytes
EP06703172A EP1844075A2 (en) 2005-01-05 2006-01-04 Suppressor of disease-associated autoreactive b iymphocytes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BG109003A BG65954B1 (en) 2005-01-05 2005-01-05 Means for selective suppression of the activity of pathologic autoreactive b-cells

Publications (2)

Publication Number Publication Date
BG109003A true BG109003A (en) 2006-07-31
BG65954B1 BG65954B1 (en) 2010-07-30

Family

ID=36647833

Family Applications (1)

Application Number Title Priority Date Filing Date
BG109003A BG65954B1 (en) 2005-01-05 2005-01-05 Means for selective suppression of the activity of pathologic autoreactive b-cells

Country Status (3)

Country Link
EP (1) EP1844075A2 (en)
BG (1) BG65954B1 (en)
WO (1) WO2006072152A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI742423B (en) 2014-05-29 2021-10-11 美商宏觀基因股份有限公司 Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
RU2731202C2 (en) 2015-10-08 2020-08-31 Макродженикс, Инк. Combined therapy for cancer treatment
WO2018175993A1 (en) * 2017-03-24 2018-09-27 Orpheus Bioscience Inc. Pantids for treatment of autoimmune disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9516760D0 (en) * 1995-08-16 1995-10-18 Sandoz Ltd Organic compounds
US6001964A (en) * 1995-09-20 1999-12-14 Albert Einstein College Of Medicine Of Yeshiva University Peptides which bind to anti-double stranded DNA antibody
US7118743B2 (en) * 1998-11-17 2006-10-10 Tanox, Inc. Bispecific molecules cross-linking ITIM and ITAM for therapy
EP1439857B1 (en) * 2001-10-12 2009-02-25 Schering Corporation USE OF BISPECIFIC ANTIBODIES BINDING TO THE ACTIVATING RECEPTOR FcEpsilonRI AND TO THE INHIBITING RECEPTOR OX2Ra (CD200Ra) TO REGULATE IMMUNE RESPONSES
BG65715B1 (en) * 2003-09-04 2009-08-31 Чавдар ВАСИЛЕВ Device for selective suppression of pathologic dna-specific b cells

Also Published As

Publication number Publication date
EP1844075A2 (en) 2007-10-17
BG65954B1 (en) 2010-07-30
WO2006072152A2 (en) 2006-07-13
WO2006072152A3 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
LTPA2017040I1 (en) Antibodies to CD38 antigen for the treatment of multiple myeloma
HK1219488A1 (en) Human monoclonal antibodies to activin receptor-like kinase-1 -1
CY1118343T1 (en) TWECK CONNECTION PARTS
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
TW200626171A (en) Fixed dosing of HER antibodies
HK1125297A1 (en) Anti-ctla-4 antibody compositions ctla-4
IL239947A (en) Anti-human il-21 monoclonal antibodies
EP2097104A4 (en) New a-beta conformer selective anti-a-beta globulomer monoclonal antibodies
HK1102760A1 (en) Anti-psgl-1 antibodies
IL179672A0 (en) Anti-cd3 antibodies
DK2019840T3 (en) Antagonist anti-human CD40 monoclonal antibody.
IL193871A0 (en) Humanized anti-cd20 monoclonal antibody
ZA200802051B (en) Anti-CD3 antibody formulations
ZA200708548B (en) P-cadherin antibodies
ZA200809662B (en) Modified humanised anti-interleukin-18 antibodies
PL1749693T3 (en) Seat for vehicle
EP1761566A4 (en) Humanized anti-tag-72 monoclonal antibodies
WO2008093688A1 (en) CHIMERIC Fcγ RECEPTOR AND METHOD FOR DETERMINATION OF ADCC ACTIVITY BY USING THE RECEPTOR
MX2009004167A (en) Antibodies that bind cxcr7 epitopes.
DE602006009124D1 (en) Vehicular child safety seat
HK1077827A1 (en) Diazabicyclononane and-decane derivatives their use as opioid receptor ligands
EP2186894A4 (en) Monoclonal antibody having neutralizing activity against mmp13
BG109003A (en) Means for selective suppression of the activity of pathologic autoreactive b-cells
UA96426C2 (en) Isolated human or humanized antibody that specifically binds to il-13
IL191150A0 (en) Cytotoxic antibodies targeting antibodies inhibiting factor viii